用99mTc-甲氧基异丁基异腈预测体内肿瘤多药耐药的研究进展

被引：2

作者：

机构：

来源：

国际药学研究杂志 | 1998年 / 01期

关键词：

多药耐药; 放射性核素显像; Tc－甲氧基异丁基异腈;

D O I：

暂无

中图分类号：

R969 [临床药理学];

学科分类号：

100602 ; 100706 ;

摘要：

多药耐药（ＭＤＲ）是影响肿瘤化疗成功的重要障碍。早期发现ＭＤＲ，从而选择较敏感的治疗药物，具有临床实用价值。最近发现，(９９m)Ｔｃ－甲氧基异丁基异腈（ｍｅｔｈｏｘｙｉｓｏｂｕｔｙｌｉｓｏｎｉｔｒｉｌｅ，简称ＭＩＢＩ）和某些细胞毒药物同为ｍｄｒ１基因表达的Ｐ－糖蛋白（Ｐ－ｇｐ）的作用废物，Ｐ－ｇｐ能将它们转运出细胞，使化疗无效，也使肿瘤不表现放射性浓集。从而提示可以用简便、无创的核医学显像方法，于化疗之前预测体内肿瘤细胞的ＭＤＲ状况，协助选择治疗药物；并可在治疗过程中随时监测ＭＤＲ的变化，以及评价药物逆转ＭＤＲ的效果。

引用

页码：5 / 9

页数：5

共 6 条

[1]

In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients[J] . Silvana Vecchio,Andrea Ciarmiello,Maria I. Potena,Maria V. Carriero,Ciro Mainolfi,Gerardo Botti,Renato Thomas,Maria Cerra,Giuseppe D’Aiuto,Takashi Tsuruo,Marco Salvatore.European Journal of Nuclear Medicine . 1997 (2)

[2]

99m Tc-MIBI scintigraphy in metastatic renal cell carcinoma: clinical validation of the relationship between 99m Tc-MIBI uptake and P-alvcoprotein expression in tumour tissue[J] . Erkan Derebek,Ziya Kirkali,A. Semih Dogan,Berna Degirmenci,Mustafa Yilmaz,Enis Igci,Kutsal Yorukoglu,llhami Kovanlikaya,Hatice Durak.European Journal of Nuclear Medicine . 1996 (8)

[3] Primary breast cancer imaging with technetium-99m sestamibi and its relation with P-glycoprotein overexpression [J].

Moretti, JL ;

Azaloux, H ;

Boisseron, D ;

Kouyoumdjian, JC ;

Vilcoq, J .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1996, 23 (08) :980-986

[4] Technetium-99m sestamibi uptake in human breast carcinoma cell lines displaying glutathione-associated drug-resistance [J].

Kabasakal, L ;

Ozker, K ;

Hayward, M ;

Akansel, G ;

Griffith, O ;

Isitman, AT ;

Hellman, R ;

Collier, D .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1996, 23 (05) :568-570

[5]

Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas[J] . A. Dimitrakopoulou-Strauss,L. G. Strauss,H. Goldschmidt,W. J. Lorenz,W. Maier-Borst,G. Kaick.European Journal of Nuclear Medicine . 1995 (5)

[6]

Sequential functional imaging with technetium-99m hexakis-2-meth oxyisobutylisonitrile and indium-111 octreotide: can we predict the response to chemotherapy in small cell lung cancer?[J] . J. L. Moretti,M. Caglar,C. Boaziz,N. Caillat-Vigneron,J. F. Morere.European Journal of Nuclear Medicine . 1995 (2)

← 1 →